Categories
Forex
+-
-
Jun 27, 2025 Premium
-
Apr 30, 2025 Premium
Crypto
+-
Jul 13, 2025 Premium
-
Jul 10, 2025 Premium
-
Jul 10, 2025 Premium
US Stock
−-
Jul 11, 2025 Premium
-
Jul 7, 2025
-
Jun 29, 2025
NGX Stock
+-
Jul 16, 2025 Premium
-
Jul 16, 2025 Premium
-
Jul 16, 2025
Gold and Silver
+Crude Oil
+-
Aug 6, 2024

Anebulo Pharmaceuticals is executing on a clear, high-impact strategy—developing an IV cannabis antidote for children—while methodically strengthening its financial position. Success hinges on meeting clinical milestones and efficient use of capital. Investors seeking early-stage biotech plays with public-sector validation and niche-first therapies may find Anebulo a compelling
TACT In An Inflection Point
Updated: 7/16/2025 4:47 AM
Bottom Line: Looking down to completed larger Wave 2
TransAct is at a strategic inflection point, pivoting from stable hardware profits to SaaS-driven growth. With BOHA! gaining enterprise-level customers, improving ARPU traction, and a legacy cash flow foundation, this modestly valued micro-cap could offer re-rating potential—contingent on continued SaaS execution and margin improvement.
(Last Price 1.71): Lacking any evidence of a turn higher at the sloped resistance, there is scope lower evidence that Aneb is in a wave 3 correction towards 1.37 region.
You May
Also
Like
Oando is transitioning from acquisition-led growth toward cash flow generation and balance sheet...
Japaul Gold & Ventures PLC shows strong financial improvement, with significant revenue growth...
Linkage Assurance Analysis July 16th, 2025...
Anebulo Pharmaceuticals is executing on a clear, high-impact strategy—developing an IV cannabis...
Ellahlakes Update July 16,2025...
Sunuassur July 15th update...

Learn More about Elliot Wave Theory
Our Clients Reviews
Read what our clients have to say about their experience with EWNation.